Prenatal screening for trisomy 21: recent advances and guidelines : Clinical Chemistry and Laboratory Medicine Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

30,00 € / $42.00 / £23.00

Get Access to Full Text

Prenatal screening for trisomy 21: recent advances and guidelines

1Division of Medical Screening and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI, USA

Corresponding author: Dr. Jacob Canick, Division of Medical Screening and Special Testing, 70 Elm Street, Providence, RI 02903, USA Phone: +1-401-453-7654, Fax: +1-401-276-7882

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 50, Issue 6, Pages 1003–1008, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/cclm.2011.671, July 2011

Publication History

Received:
2011-04-22
Accepted:
2011-06-20
Published Online:
2011-07-27

Abstract

The performance of prenatal screening tests for the identification of trisomy 21 (Down syndrome) has markedly improved since the 1970s and early 1980s when maternal age was the sole mode of screening the general pregnant population. With the discovery of second trimester serum markers in the 1980s and 1990s and implementation of double, triple, and quad marker testing; the discovery of first trimester serum and ultrasound markers in the 1990s and implementation of the combined test; and the development of the integrated test and sequential screening strategies over the past decade, the performance of screening has improved to a detection rate of 90%–95% at a false positive rate of 2%–5%. In this review, I will describe the advances in prenatal screening for trisomy 21, present current screening strategies, and discuss guidelines published by professional societies and regulatory bodies, with a focus on current prenatal screening practice in the USA.

Keywords: Down syndrome; multiple markers; prenatal screening; trisomy 21

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
J. Han, M. Pan, L. Zhen, X. Yang, Y-M. Ou, C. Liao, and D-Z. Li
Journal of Obstetrics & Gynaecology, 2014, Volume 34, Number 8, Page 669
[2]
S. Brun, M.C. Leguy, A. Bruneel, T. Fournier, O. Anselem, and J. Guibourdenche
Placenta, 2014, Volume 35, Number 6, Page 425

Comments (0)

Please log in or register to comment.